A detailed history of Two Sigma Investments, LP transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, Two Sigma Investments, LP holds 618,914 shares of SRRK stock, worth $22.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
618,914
Previous 800,672 22.7%
Holding current value
$22.9 Million
Previous $6.67 Million 25.67%
% of portfolio
0.01%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.63 - $9.71 $1.39 Million - $1.76 Million
-181,758 Reduced 22.7%
618,914 $4.96 Million
Q2 2024

Aug 14, 2024

BUY
$7.84 - $16.79 $3.76 Million - $8.06 Million
479,853 Added 149.57%
800,672 $6.67 Million
Q1 2024

May 15, 2024

BUY
$13.2 - $17.76 $3.18 Million - $4.28 Million
240,862 Added 301.24%
320,819 $5.7 Million
Q4 2023

Feb 14, 2024

BUY
$6.52 - $20.32 $370,055 - $1.15 Million
56,757 Added 244.64%
79,957 $1.5 Million
Q3 2023

Nov 14, 2023

SELL
$6.02 - $7.76 $6,020 - $7,760
-1,000 Reduced 4.13%
23,200 $164,000
Q2 2023

Aug 14, 2023

BUY
$5.79 - $9.11 $58,479 - $92,011
10,100 Added 71.63%
24,200 $182,000
Q1 2023

May 15, 2023

BUY
$7.36 - $12.72 $103,776 - $179,352
14,100 New
14,100 $112,000
Q2 2022

Aug 15, 2022

SELL
$4.66 - $13.96 $112,306 - $336,436
-24,100 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$11.89 - $24.68 $286,549 - $594,788
24,100 New
24,100 $311,000
Q3 2021

Nov 15, 2021

SELL
$27.38 - $42.21 $940,064 - $1.45 Million
-34,334 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$26.34 - $46.62 $904,357 - $1.6 Million
34,334 New
34,334 $992,000
Q3 2020

Nov 16, 2020

SELL
$10.54 - $18.47 $155,454 - $272,414
-14,749 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$10.37 - $20.64 $152,947 - $304,419
14,749 New
14,749 $269,000

Others Institutions Holding SRRK

About Scholar Rock Holding Corp


  • Ticker SRRK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,640,600
  • Market Cap $1.91B
  • Description
  • Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...
More about SRRK
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.